Blue Goat CyberBlue Goat CyberSMMedical Device Cybersecurity
    K
    Blog · Pen Testing

    Post-Exploitation Frameworks in MedTech

    Learn what post-exploitation frameworks (like Empire) mean for medical device cybersecurity - plus detection priorities, controls, and testing guidance.

    Abstract network nodes and glowing data streams symbolize the interconnectedness and vulnerability of medical devices
    On this page
    Christian Espinosa, Founder & CEO at Blue Goat Cyber

    By Christian Espinosa, MBA, CISSP

    Founder & CEO · Blue Goat Cyber

    Published: February 15, 2024 · Last reviewed: May 1, 2026

    Key Takeaways

    • Post-exploitation frameworks enable attackers to operate after initial compromise-often through C2 and identity abuse.
    • For medical device cybersecurity, the highest-risk paths often involve cloud backends, remote access, and update infrastructure.
    • Defenders should focus on detectable outcomes: C2 behaviors, privilege changes, lateral movement, and data staging.
    • Structured, authorized testing (referencing NIST guidance) helps you validate readiness without creating attacker how-to content.

    Part of our medtech cybersecurity framework choice series (SPDF, JSP2, IEC 81001-5-1). For the full overview, start with JSP2 vs SPDF vs IEC 81001-5-1: Framework Pick.

    Direct Answer

    Post-Exploitation Frameworks against medical devices are practical, not theoretical. Here's how the attack chain works, what FDA reviewers look for, and the controls that stop it in 2026.

    What is “post-exploitation”?

    Post-exploitation refers to what happens after initial compromise: actions an adversary takes to increase capability and achieve objectives (e.g., persistence, privilege escalation, credential access, and data collection). Frameworks help orchestrate these activities at scale.

    For defenders, the key insight is simple: initial access is not the end of the story. The higher-impact damage often comes later-when an attacker moves to higher-value systems and establishes command-and-control (C2) communications.

    MITRE ATT&CK describes the Command and Control tactic as the adversary communicating with compromised systems to control them-often by mimicking normal traffic to avoid detection.

    MITRE ATT&CK: Command and Control (TA0011)

    Why post-exploitation matters for connected medical devices

    Medical device cybersecurity isn’t just firmware security. Most modern products rely on an ecosystem:

    • Cloud services (telemetry, dashboards, remote configuration)
    • Identity and access management (IAM)
    • Software update infrastructure (build pipelines, signing, distribution)
    • Field service tooling and support access
    • Hospital networks where devices operate

    Post-exploitation frameworks target the same layers. That’s why mature manufacturers treat post-exploitation as a design input for monitoring, incident response, and postmarket readiness-not just something “IT security handles.”

    What defenders should focus on (instead of tool details)

    You don’t need to memorize every offensive feature to defend effectively. Focus on outcomes you can detect and control:

    1) Command-and-control behaviors

    • Unexpected outbound connections from systems that should be “quiet”
    • Beaconing patterns (regular intervals, unusual destinations)
    • Abnormal DNS behavior (high volume, strange subdomains)
    • Proxy bypass and direct-to-internet traffic where it shouldn’t exist

    2) Identity abuse and privilege changes

    • New admin accounts or role assignments
    • Unusual token issuance and refresh activity
    • Service account misuse (interactive logins, odd source IPs)

    3) Lateral movement and remote execution

    • Unexpected remote management activity
    • New remote service creation
    • Authentication “spray” patterns and failed logon spikes

    4) Data staging and exfiltration precursors

    • Archive/compression activity in unusual locations
    • Large outbound transfers or repeated small transfers to rare destinations
    • Access to repositories holding signing keys, build artifacts, or device secrets

    MedTech translation: if an attacker compromises your update pipeline or signing process, you can move from a security incident to a large-scale patient safety and field impact problem quickly.

    How this ties to FDA lifecycle cybersecurity expectations

    FDA’s cybersecurity guidance emphasizes building and maintaining cybersecurity across the Total Product Lifecycle (TPLC)-including processes that support monitoring, response, and ongoing risk control.

    Post-exploitation considerations support that lifecycle view by driving concrete engineering decisions:

    • What must be logged (device/app/cloud/update infrastructure)
    • What must be monitored (identity, C2, privileged actions)
    • How incident investigations will be executed and documented
    • How findings flow into risk management and CAPA

    FDA: Cybersecurity in Medical Devices (Premarket Guidance)

    What “good” looks like: a practical readiness checklist

    Logging and visibility

    See also: Medical Device Pen Testing, Medical Device Robustnesss & Fuzz Testing, and Scoping A Medical Device Penetration Test.

    • Centralized collection for cloud audit logs, IAM changes, and admin actions
    • Retention aligned to your incident response reality (not the minimum)
    • Time synchronization across device, cloud, and build systems

    Segmentation and access control

    • Separation between corporate IT and product environments (especially build/signing)
    • Strong controls on remote support channels and field tooling
    • Least privilege for service accounts and CI/CD automation

    Response capability

    • Clear incident runbooks for “C2 suspected,” “credential compromise,” and “build pipeline integrity”
    • Defined evidence collection procedures and ownership
    • Regular exercises that include engineering and quality stakeholders

    How to test for post-exploitation risk ethically (and defensibly)

    Post-exploitation risk should be evaluated through authorized, scoped security testing with documented rules of engagement.

    NIST SP 800-115 provides a practical foundation for planning and conducting technical security tests, analyzing findings, and developing mitigation strategies. It’s a helpful reference for structuring assessments and making results actionable.

    NIST SP 800-115: Technical Guide to Information Security Testing and Assessment

    For medical device organizations, testing commonly includes:

    Common mistakes we see in MedTech environments

    • Assuming “device security” is separate from cloud and identity security. Most real incidents cross boundaries.
    • Weak protection of build/signing systems. These are high-value targets.
    • Logging without ownership. If no one can investigate quickly, logs won’t save you.
    • Exercises that exclude engineering and quality. The response stalls when handoffs are unclear.

    How Blue Goat approaches this

    Blue Goat Cyber helps medical device manufacturers prepare for, detect, and respond to post-exploitation tactics. Our methodology, refined by CISSP, OSCP, and ex-military red team experts, focuses on practical, verifiable security enhancements. We identify weaknesses in your device ecosystems, including cloud services, IAM, and software update infrastructure, that adversaries could exploit.

    Our services go beyond theoretical assessments, emphasizing actionable strategies for monitoring C2 behaviors, detecting identity abuse, and tracing lateral movement. We perform targeted security testing to simulate real-world post-exploitation scenarios, ensuring your defenses are truly effective. Our commitment extends to regulatory success: if the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. We partner with you to build resilience into your device security posture. Learn more about our postmarket readiness at: https://www.bluegoatcyber.com/services/fda-postmarket-cybersecurity-services

    FAQ

    What is a post-exploitation framework?

    A post-exploitation framework is a toolset used after a system is compromised to help an adversary maintain control, expand access, and execute objectives. Defenders use knowledge of these behaviors to improve detection and response.

    Why should medical device manufacturers care about post-exploitation?

    Because connected medical devices rely on cloud services, identity systems, and update infrastructure-common targets for post-compromise activity. Compromise of these systems can drive broad operational and patient-impact risk.

    How do we defend against command-and-control (C2) activity?

    Start with strong egress controls, DNS monitoring, centralized cloud/IAM logging, and detections mapped to common C2 behaviors. MITRE ATT&CK’s Command and Control tactic is a useful organizing lens.

    Should we include post-exploitation in penetration testing?

    If authorized and scoped, yes-because it demonstrates realistic impact. Use clear rules of engagement, avoid unnecessary disruption, and ensure findings translate into mitigations and monitored detections.

    How does this relate to FDA cybersecurity expectations?

    The FDA emphasizes lifecycle cybersecurity. Post-exploitation considerations strengthen monitoring, investigation, and remediation processes by clarifying what must be logged, detected, and exercised across the product ecosystem.

    Next step

    If you want to validate your detection and response readiness for post-compromise behaviors-especially across cloud backends and update infrastructure-we can help you build a practical, FDA-aligned plan.

    Book a Discovery Session

    Select all squares with motorcycles If there are none, click skip

    Skip

    About the author

    Christian Espinosa, Founder & CEO at Blue Goat Cyber

    Christian Espinosa, MBA, CISSP · Founder & CEO, Blue Goat Cyber

    U.S. Air Force Academy graduate and veteran with 30+ years in cybersecurity. Founded Alpine Security in 2014 (acquired 2020), then Blue Goat Cyber in 2022. Has supported 250+ FDA medical device submissions; no client has failed to clear due to cybersecurity. Author of three books including The Smartest Person in the Room. Ironman triathlete and mountaineer.

    Read more about ChristianLinkedIn

    Sources & references

    Primary sources cited in this article. Links open in a new tab.

    1. MITRE ATT&CK: Command and Control (TA0011)- MITRE
    2. FDA: Cybersecurity in Medical Devices (Premarket Guidance)- U.S. FDA
    3. NIST SP 800-115: Technical Guide to Information Security Testing and Assessment- NIST
    More in this category

    More Pen Testing articles

    Browse all
    Related 524B & eSTAR resources

    Keep going: the 524B and eSTAR working set

    Start with the walkthrough hub, then drill into the statute, the eSTAR field map, SBOM monitoring, postmarket planning, and deficiency response. Use these as the playbook behind every cyber device submission.

    Hub
    FDA Section 524B & eSTAR Cybersecurity Walkthrough

    Start here: the hub that ties the statute, the February 2026 guidance, and the eSTAR fields together in the order a submission team works through them.

    Related services

    Put this into practice on your device

    Every Blue Goat Cyber engagement maps directly to FDA Section 524B and the SPDF - so the evidence you need lands in your submission, not in a separate report.

    Ready when you are

    Get FDA cleared without the cybersecurity headaches.

    30-minute strategy session. No cost, no commitment - just answers from people who've shipped 250+ FDA submissions.